Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Net Income (2016 - 2025)

Editas Medicine (EDIT) has disclosed Net Income for 11 consecutive years, with -$25.1 million as the latest value for Q3 2025.

  • Quarterly Net Income rose 59.58% to -$25.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$197.6 million through Sep 2025, up 6.13% year-over-year, with the annual reading at -$237.1 million for FY2024, 56.38% down from the prior year.
  • Net Income for Q3 2025 was -$25.1 million at Editas Medicine, up from -$51.5 million in the prior quarter.
  • The five-year high for Net Income was -$18.9 million in Q4 2023, with the low at -$75.7 million in Q1 2025.
  • Average Net Income over 5 years is -$51.4 million, with a median of -$53.7 million recorded in 2022.
  • The sharpest move saw Net Income soared 68.95% in 2023, then plummeted 140.68% in 2024.
  • Over 5 years, Net Income stood at -$55.3 million in 2021, then decreased by 9.92% to -$60.7 million in 2022, then skyrocketed by 68.95% to -$18.9 million in 2023, then tumbled by 140.68% to -$45.4 million in 2024, then soared by 44.67% to -$25.1 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$25.1 million, -$51.5 million, and -$75.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.